PURPOSE: To determine the role of the fluorine-18 fluorodeoxyglucose positron emission tomography (FDG-PET) scan in the diagnosis and management of deep septic thrombophlebitis (STP). PATIENTS AND METHODS: We conducted a prospective observational evaluation of FDG-PET in patients with cancer and suspected STP. Retrospective evaluation of patients with cancer and deep venous thrombosis (DVT) who underwent FDG-PET and extremity duplex scan (DS) was also performed. RESULTS: Strong venous uptake was observed in FDG-PET of nine STP episodes versus 0 of 27 DVT episodes (P <.001). FDG-PET identified central vein STP in five patients, whereas DS and venography were negative in five and two of these patients, respectively. FDG-PET diagnosis of STP resulted in therapeutic changes in all patients. In four patients, follow-up FDG-PET confirmed resolution. CONCLUSION: In cancer patients, FDG-PET identifies STP even in areas not optimally visualized by DS or venography, distinguishes STP from DVT, and leads to significant therapeutic changes.
PURPOSE: To determine the role of the fluorine-18 fluorodeoxyglucose positron emission tomography (FDG-PET) scan in the diagnosis and management of deep septic thrombophlebitis (STP). PATIENTS AND METHODS: We conducted a prospective observational evaluation of FDG-PET in patients with cancer and suspected STP. Retrospective evaluation of patients with cancer and deep venous thrombosis (DVT) who underwent FDG-PET and extremity duplex scan (DS) was also performed. RESULTS: Strong venous uptake was observed in FDG-PET of nine STP episodes versus 0 of 27 DVT episodes (P <.001). FDG-PET identified central vein STP in five patients, whereas DS and venography were negative in five and two of these patients, respectively. FDG-PET diagnosis of STP resulted in therapeutic changes in all patients. In four patients, follow-up FDG-PET confirmed resolution. CONCLUSION: In cancerpatients, FDG-PET identifies STP even in areas not optimally visualized by DS or venography, distinguishes STP from DVT, and leads to significant therapeutic changes.
Authors: Matthew T Rondina; Uyen T Lam; Robert C Pendleton; Larry W Kraiss; Nathan Wanner; Guy A Zimmerman; John M Hoffman; Christopher Hanrahan; Kenneth Boucher; Paul E Christian; Regan I Butterfield; Kathryn A Morton Journal: Clin Nucl Med Date: 2012-12 Impact factor: 7.794
Authors: Stephen D Guy; Adrian R Tramontana; Leon J Worth; Eddie Lau; Rodney J Hicks; John F Seymour; Karin A Thursky; Monica A Slavin Journal: Eur J Nucl Med Mol Imaging Date: 2012-05-15 Impact factor: 9.236
Authors: Fatemeh Kaghazchi; Austin J Borja; Emily C Hancin; Abhijit Bhattaru; Donald K E Detchou; Siavash Mehdizadeh Seraj; Chaitanya Rojulpote; Soren Hess; Lorenzo Nardo; Peter E Gabriel; Scott M Damrauer; Thomas J Werner; Abass Alavi; Mona-Elisabeth Revheim Journal: Am J Nucl Med Mol Imaging Date: 2021-04-15